The Lung Cancer Research Foundation and Free to Breathe announced a merger to make an even greater impact on closing the funding gap for lung cancer research. The New York State Attorney General approved the required merger documentation on Sept. 30.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
